<DOC>
	<DOCNO>NCT00025298</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining radiation therapy chemotherapy may kill tumor cell . Giving chemoprotective drug amifostine may protect normal cell side effect chemotherapy radiation therapy . PURPOSE : Randomized phase II trial compare effectiveness paclitaxel carboplatin follow cisplatin plus radiation therapy without amifostine treat patient locally advanced cancer nasopharynx .</brief_summary>
	<brief_title>Chemotherapy Plus Radiation Therapy With Without Amifostine Treating Patients With Locally Advanced Cancer Nasopharynx</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall incidence grade 3 4 mucositis patient locally advance undifferentiated nasopharyngeal cancer treat paclitaxel carboplatin follow cisplatin radiotherapy without amifostine . - Compare feasibility activity regimens patient . - Determine toxicity paclitaxel carboplatin patient . OUTLINE : This randomize , multicenter study . Patients stratify accord WHO performance status ( 0 vs 1 v 2 ) , response induction chemotherapy ( complete vs partial v stable disease v evaluable ) , participate center . Patients receive induction chemotherapy comprise paclitaxel IV 3 hour carboplatin IV 30 minute day 1 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients complete partial response 2 course induction chemotherapy receive 2 additional course randomization . Patients stable disease 2 course induction chemotherapy evaluate 1 course proceed directly randomization . Patients randomize 1 2 treatment arm . - Arm I : Patients receive cisplatin IV day 1 , 22 , 43 . Patients also undergo radiotherapy daily 5 day week 6.5 week . - Arm II : Patients receive amifostine subcutaneously daily . Patients receive chemotherapy radiotherapy arm I . Patients follow every 3 month 2 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 41-93 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm undifferentiated nasopharyngeal cancer ( UNPC ) Locoregionally advanced disease T2b , N1 ( great 3 cm ) N2 T3 , N1 ( great 3 cm ) N2 T4 , N1 ( great 3 cm ) N2 Any T , N3 No squamous cell histology At least 1 unidimensionally measurable target lesion At least 20 mm conventional technique OR At least 10 mm spiral CT scan No evidence distant metastases No sign symptom CNS metastases PATIENT CHARACTERISTICS : Age : 15 70 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 2,000/mm^3 Platelet count least 150,000/mm^3 Hemoglobin least 12 g/dL Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST/ALT great 2.5 time ULN Renal : Creatinine clearance least 70 mL/min Calcium normal Cardiovascular : No hypotension hypertension require therapy No prior myocardial infraction No preexisting uncontrolled cardiac disease No sign cardiac failure No rhythm disturbance require medication Other : No sensory neuropathy grade 2 great unless due cranial nerve No uncontrolled infection No sensitivity aminothiol compound No malignancy within past 5 year except adequately control carcinoma situ cervix basal cell squamous cell skin cancer No psychological , familial , sociological , geographical condition would preclude study Fertile patient must use effective contraception 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : No prior chemotherapy UNPC Endocrine therapy : No concurrent hormonal therapy except corticosteroid antiemetic prophylaxis Radiotherapy : No prior radiotherapy UNPC Surgery : No prior surgery UNPC except cervical lymphadenectomy Other : At least 1 month since prior investigational agent No concurrent anticancer drug</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>stage II nasopharyngeal cancer</keyword>
	<keyword>stage III nasopharyngeal cancer</keyword>
	<keyword>stage IV nasopharyngeal cancer</keyword>
	<keyword>oral complication</keyword>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>radiation toxicity</keyword>
</DOC>